Oct 2026· Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie· Vol 204, pp.
119987
· 0 citations· 51 references
Medicine
TL;DR
LIT-01-144 is designed and characterized, a modified spexin analog incorporating N-terminal fluorocarbon functionalization to improve metabolic stability while preserving receptor selectivity, and demonstrated the potential of LIT-01-144 as a valuable tool for understanding GALR2-mediated mechanisms of pain modulation.
Abstract
Chronic pain constitutes a major global health burden, and current management remains largely dependent on opioid analgesics, which are associated with opioid use disorder. Accordingly, there is a pressing need to identify non-opioid therapeutic strategies. Galanin receptors (GALR1-3) have been implicated in pain modulation, but their individual roles remain insufficiently defined because of the absence of subtype-selective ligands. Recently, spexin has been identified as an endogenous peptide that selectively activates GALR2 and GALR3, offering a new scaffold for developing pharmacological tools targeting these receptor subtypes. In this study, we designed and characterized LIT-01-144, a modified spexin analog incorporating N-terminal fluorocarbon functionalization to improve metabolic stability while preserving receptor selectivity. In vitro pharmacological profiling demonstrated high potency at GALR2 and GALR3, with negligible activity at GALR1. Pharmacokinetic analyses showed a substantially prolonged plasma half-life relative to native spexin and no evidence of central nervous system penetration. In vivo, intracerebroventricular administration of LIT-01-144 produced robust antinociception at doses tenfold lower than those required for spexin. Although systemic administration had no detectable effect in naïve mice, it significantly attenuated pain-related behaviors in a model of persistent inflammatory pain. This effect was mediated specifically by GALR2 and was independent of opioid receptor signaling. In situ hybridization further showed an increase in Galr2 + neurons in dorsal root ganglia of inflamed mice. Collectively, these findings highlight GALR2 as a promising peripheral target for developing non-opioid analgesics and demonstrate the potential of LIT-01-144 as a valuable tool for understanding GALR2-mediated mechanisms of pain modulation.
Pharmacokinetic studies identified compound 10 as a P-glycoprotein substrate with limited brain exposure, consistent with a CNS-sparing profile and preferentially peripheral activity, and was identified as a KOR-mediated antinociception candidate.
Ahmed M. Reda, Logan T. Neel, Celsey M. St. Onge et al.· Journal of Medicinal Chemist...· 0 citations
Neurotensin (NT)-based ligands represent promising non-opioid analgesics. Here, we designed and synthesized a focused library of macrocyclic NT analogs combining substitutions previously shown to enhance NTS2 affinity, selectivity, and/or antinociceptive activity. Several macrocycles retained low-nanomolar NTS2 affinit...
Michael Desgagné, Nathan Meneboo, Magali Chartier et al.· Journal of Medicinal Chemist...· 0 citations
These studies provide evidence about the in vivo behavioral and neurometabolic profiles of fentanyl after pretreatment with CBD and synthetic CBD, presenting them as possible pharmacological tools for OUD research.
Dalal A. Alkhelb, Jomana M. Alahmadi, Maisa S. Alqarni et al.· Molecules· 0 citations
Piperazine-1-ium derivative 24a stands out as the first permanently charged CB1R antagonist, exhibiting nanomolar affinity and high CB1R/CB2R selectivity with a favorable physicochemical profile consistent with peripheral restriction and limited blood-brain barrier penetration.
J. Azuaje, Rubén Prieto-Díaz, Claudia Gioé-Gallo et al.· ACS Omega· 0 citations
The metabotropic glutamate receptor 7 (mGlu7) is an emerging therapeutic target for central nervous system disorders, but progress has been limited by a lack of selective pharmacological tools. CVN636 was recently reported as a potent and selective allosteric agonist of this receptor, capable of receptor activation in...
Xin Lin, C. Niswender, Wesley B. Asher et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.